Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Bioorg Med Chem Lett ; 25(1): 75-82, 2015 Jan 01.
Artigo em Inglês | MEDLINE | ID: mdl-25466195

RESUMO

Optimization of 5-(2,6-dichlorophenyl)-3-hydroxy-2-mercaptocyclohex-2-enone using structure-based design strategies resulted in inhibitors with considerable improvement in biochemical potency against human lactate dehydrogenase A (LDHA). These potent inhibitors were typically selective for LDHA over LDHB isoform (4­10 fold) and other structurally related malate dehydrogenases, MDH1 and MDH2 (>500 fold). An X-ray crystal structure of enzymatically most potent molecule bound to LDHA revealed two additional interactions associated with enhanced biochemical potency.


Assuntos
Inibidores Enzimáticos/síntese química , L-Lactato Desidrogenase/antagonistas & inibidores , Animais , Cristalografia por Raios X , Cães , Inibidores Enzimáticos/metabolismo , Inibidores Enzimáticos/farmacologia , Humanos , L-Lactato Desidrogenase/metabolismo , Células Madin Darby de Rim Canino
2.
Bioorg Med Chem Lett ; 24(16): 3764-71, 2014 Aug 15.
Artigo em Inglês | MEDLINE | ID: mdl-25037916

RESUMO

A novel class of 3-hydroxy-2-mercaptocyclohex-2-enone-containing inhibitors of human lactate dehydrogenase (LDH) was identified through a high-throughput screening approach. Biochemical and surface plasmon resonance experiments performed with a screening hit (LDHA IC50=1.7 µM) indicated that the compound specifically associated with human LDHA in a manner that required simultaneous binding of the NADH co-factor. Structural variation of this screening hit resulted in significant improvements in LDHA biochemical inhibition activity (best IC50=0.18 µM). Two crystal structures of optimized compounds bound to human LDHA were obtained and explained many of the observed structure-activity relationships. In addition, an optimized inhibitor exhibited good pharmacokinetic properties after oral administration to rats (F=45%).


Assuntos
Cicloexanonas/farmacologia , Inibidores Enzimáticos/farmacologia , L-Lactato Desidrogenase/antagonistas & inibidores , Compostos de Sulfidrila/farmacologia , Administração Oral , Animais , Cicloexanonas/administração & dosagem , Cicloexanonas/química , Relação Dose-Resposta a Droga , Inibidores Enzimáticos/administração & dosagem , Inibidores Enzimáticos/química , Ensaios de Triagem em Larga Escala , Humanos , L-Lactato Desidrogenase/metabolismo , Modelos Moleculares , Estrutura Molecular , Ratos , Relação Estrutura-Atividade , Compostos de Sulfidrila/administração & dosagem , Compostos de Sulfidrila/química
3.
Bioorg Med Chem Lett ; 23(11): 3186-94, 2013 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-23628333

RESUMO

A novel 2-thio-6-oxo-1,6-dihydropyrimidine-containing inhibitor of human lactate dehydrogenase (LDH) was identified by high-throughput screening (IC50=8.1 µM). Biochemical, surface plasmon resonance, and saturation transfer difference NMR experiments indicated that the compound specifically associated with human LDHA in a manner that required simultaneous binding of the NADH co-factor. Structural variation of the screening hit resulted in significant improvements in LDHA biochemical inhibition activity (best IC50=0.48 µM). A crystal structure of an optimized compound bound to human LDHA was obtained and explained many of the observed structure-activity relationships.


Assuntos
Inibidores Enzimáticos/química , L-Lactato Desidrogenase/antagonistas & inibidores , Pirimidinas/química , Sítios de Ligação , Cristalografia por Raios X , Inibidores Enzimáticos/síntese química , Inibidores Enzimáticos/metabolismo , Humanos , Ligação de Hidrogênio , L-Lactato Desidrogenase/metabolismo , Espectroscopia de Ressonância Magnética , NAD/metabolismo , Ligação Proteica , Estrutura Terciária de Proteína , Pirimidinas/síntese química , Pirimidinas/metabolismo , Relação Estrutura-Atividade , Ressonância de Plasmônio de Superfície
4.
ACS Med Chem Lett ; 7(10): 896-901, 2016 Oct 13.
Artigo em Inglês | MEDLINE | ID: mdl-27774125

RESUMO

A series of trisubstituted hydroxylactams was identified as potent enzymatic and cellular inhibitors of human lactate dehydrogenase A. Utilizing structure-based design and physical property optimization, multiple inhibitors were discovered with <10 µM lactate IC50 in a MiaPaca2 cell line. Optimization of the series led to 29, a potent cell active molecule (MiaPaca2 IC50 = 0.67 µM) that also possessed good exposure when dosed orally to mice.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA